Openbookopenbook
Equity
LQDA
+0.0 · +0.00%
USD · NASDAQ

Liquidia Technologies Inc(LQDA) Stock Analysis | Healthcare

USD --+0.00%
Reward63Moderate
Risk50Moderate
75%Data
Strong 31% profit margin · Revenue growing 1843% YoY
Growth Machine
Market Cap:6.06Bn
ⓘ
Reward Rating
63
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
50
Moderate
Risk Assessment
6 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LQDA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for LQDA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $107.75.

What is Liquidia Technologies Inc?

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.

LQDA · Verdict

Solid reward · moderate risk

LQDA stands out on growth and volatility, but watch the cash flow signal.

Based on 88% data coverage

LQDA · Verdict

What’s working & what to watch

Strengths 2

  • Growth81/100

    Rev +115.0% CAGR · earnings +18.9%

  • Volatility80/100

    Top decile vs peers

Watchouts 2

  • Cash flow16/100

    -25% free-cash-flow margin

  • Balance sheet18/100

    Current ratio 1.40

Model-based scoring. For information only — not financial advice.

What is Liquidia Technologies Inc?

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 6.06B, and a P/E ratio of 48.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (63)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

KNSAMid Cap / 6B market cap
Kiniksa Pharmaceuticals Ltd
Compare
AMRXMid Cap / 6.2B market cap
Amneal Pharmaceuticals, Inc. Class A Common Stock
Compare
LNTHMid Cap / 6.6B market cap
Lantheus Holdings Inc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap6.06B
P/E Ratio48.35
Dividend YieldN/A
Beta0.572
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
19576,556 shares
$22.7M
0
6-9months
11,580 shares
$66k
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.